Insulin-like Growth Factor System in Hepatocarcinogenesis

ISSN 1007-7626 CN 11-3870 / Q http / / cjbmb bjmu edu cn Chinese Journal of Biochemistry and Molecular Biology 2011 5 27 5 391 ~ 396 1 2 1 2 2 * 1 100022 2 102206 IGF IGF1 IGF2 IGF1R IGF2R IGFBP Q1 Insulin-like Growth Factor System in Hepatocarcinogenesis 1 CAI Mi 2 1 HE Fu-Chu 2 ZHOU Gang-Qiao 2 * 1 College of Life Sciences and Biotechnology Beijing University of Technology Beijing 100022 China 2 State Key Laboratory of Proteomics Beijing Proteome Research Center Beijing Institute of Radiation Medicine Beijing 102206 China Abstract Hepatocellular carcinoma HCC is one of the most common cancers and ranks the fifth of the cancer mortality worldwide The complex interplay of multiple genetic and environmental factors is responsible for hepatocarcinogenesis among which the insulin-like growth factor IGF system composed of IGFs their receptors IGF1R and IGF2R and IGF binding proteins IGFBPs plays pivotal roles in the development of HCC as shown by accumulating evidences This review focuses on the recent studies about the IGF system members in hepatocarcinogenesis The development of anti-neoplasia drugs targeting the IGF system members for the treatment of HCC will be discussed Currently certain monoclonal antibodies small molecule inhibitors and antisense interference agents have been proven to be effective in inhibiting growth and promoting apoptosis of hepatic tumor cells Key words insulin-like growth factor system hepatocellular carcinoma problem and prospect hepatocellular carcinoma HCC 3 IGF IGF2 2010-12-27 2011-03-11 1 No 2008ZX10002-016 * Tel / Fax 010-80705255 E-mail zhougq114@ gmail com insulin-like growth factor IGF Received December 27 2010 Accepted March 11 2011 Supported by Chinese National Key Project for Infectious Diseases No IGFs 20 2008ZX10002-016 * Corresponding author Tel / Fax 010-80705255 E-mail zhougq114@ gmail com insulin-like growth factor receptor IGFR

392 27 1 IGF1 IGF2 IGF1R IGF2R HpG2 insulin-like growth factor binding protein IGFBP IGF1 IGF1 2 IGF1 IGF2 1α hypoxia inducible factor 1-α HIF1α IGF1 IGF1R IGF2R IGFs IGF1 IGF1R 9 matrix IGF1R 2 Raf / metalloproteinase 9 MMP-9 Raf / MAPK 3 IGF1R / AKT PI3K / AKT MMP-2 6 3 IGF2R Oliver-Marston 7 IGF1 IGF2 IGF2 IGF1 70% TGF-β1 4 IGFBP 6 IGF IGFBP1 ~ 6 IGF IGF1 5 Fig 1 Fig 1 IGF signaling pathway The biological activity of IGFs is mediated by the IGF1R mainly through two major downstream signal transduction pathways Raf / MAPK and PI3K / AKT pathway affecting cell proliferation differentiation and apoptosis The biological activity of IGFs is mainly regulated by IGFBPs The membrane protein IGF2R specifically inhibits the function of IGF2 in signal transduction activate inhibit 2 IGF1 2 1 IGF1 IGF1 8 Huynh 9 IGF1 mrna IGF1 10 IGF1 IGF1 Price 11 IGF1 IGF1 C6 IGF1 IGF1 IGF1 Kasprzak 122001 ~ 2005

5 393 10 5 40 8 IGF1 IGF2 Thorgeirsson 18 21 7 7 ~ 9 80% IGF2 Tang 19 HBV IGF1 IGF2 P1 P3 P4 P3 P4 IGF2 2 2 IGF2 IGF2 IGF2 P4 P4 20 IGF2 30% IGF2 ~ 40% IGF2 IGF2 IGF2 13 IGF2 p53 HCC IGF TGF-α IGF AFP Sun 21 IGF2 6 12 18 HBx IGF1R Breuhahn 14 IGF1R GO 155 IGF2 47 Nussbaum AFP 15 sirna IGF2 4 IGF2 IGF1R IGF2 / IGF1R 3 IGF2 28% 3 1 IGF1R IGF1R IGF2 IGFs IGF1R HGF IGF2 IGF1R IGF2 / IGF1R 22 IGF1R IGF2 11p15 5 4 P1 ~ P4 IGF1R vascular endothial growth factor IGF2 VEGF epidermal growth factor 16 IGF2 EGFR HER2 / Neu P1 EGFR IGF1R EGFR EGFR P1 IGF2 IGF2 50% P3 extracellular regulated protein kinases ERK EGFR 70% IGF2 P3 ERK 23 P2 P4 17 IGF2 / IGF1R

394 27 IGF1R / IGF2R EGFR EGFR IGF2 IGF2 / M6PR IGF2 24 IGF1 IGF2 IGF1R IGF2 / M6PR 6q26-q27 Jones Lopez 25 26 IGF1R IGF2R IGF1R M6P / IGF2 SV40LT c-myc IGF-2 IGF2 / M6PR Codoret 27c-myc IGF1R IGF2 / M6PR IGF2 / M6PR IGF1R IGF1R 4 IGF1R IGF1R IGF1R IGF IGFs IGF1R insulin IGF1R IGFs receptor IR IGFBP3 IGFBP IGF1R IR IGFBP3 IGFs 28 IGF1R IGFs IGF1R Huynh 9 Western IGFBP3 28 5% IGF1R IGFBP3 71 5% IGFR IMC-A12 IGFBP3 IGF1R IGFBP3 OSI-906 I IGFBP3 IGF1 3 2 IGF2 / M6PR IGF2 / M6PR IGF2 / M6PR M6P IGFBP IGFs IGF2 IGF1R 33 M6P Ricort 34 ~ 36 MCF-7 IGF2 IGF2 / M6PR IGF2 DNA 29 31 99% IGFBPs IGFs IGFs 32 IGFBP3 IGFBP3 IGFBP3-3 G Sedlaczek 30 IGFBP3 18 IGF2 IGF1R IGFBP3

5 395 References IGFBP3 IGFs IGFs IGFs IGFBP IGFBP IGFBP IGFBPs IGFs 29 IGFBP IGFs IGFBP IGF1R 215 37 ~ 39 IGFBP3 RRR-α- E VSE D A 4- N- hydroxyphenyl retinamide 4-HPR fenretinide IGFBP3 Nat Rev Endocrinol 2011 7 1 11-24 40 IGFBP 7 Olivo-Marston S E Hursting S D Lavigne J et al 5 1 Sanyal A J Yoon S K Lencioni R The etiology of hepatocellular carcinoma and consequences for treatment J Oncologist 2010 15 S4 14-22 2 Weng C J Hsieh Y H Tsai CM et al Relationship of insulinlike growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular IGFs J RNA IGF- 41 carcinoma J Ann Surg Oncol 2010 17 7 1808-1815 3 Annenkov A The insulin-like growth factor IGF receptor type 1 IGF1R as an essential component of the signalling network regulating neurogenesis J Mol Neurobiol 2009 40 3 195-4 Martin-Kleiner I Gall Troselj K Mannose-6-phosphate / insulinlike growth factor 2 receptor M6P / IGF2R in carcinogenesis J Cancer Lett 2010 289 1 11-22 5 Mohan S Baylink D J IGF-binding proteins are multifunctional and act via IGF-dependent and-independent mechanisms J J Endocrinol 2002 175 1 19-31 6 Clayton P E Banerjee I Murray P G et al Growth hormone the insulin-like growth factor axis insulin and cancer risk J Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice J Mol Carcinog 2009 48 12 1071-1076 8 Elsammak M Y Amin G M Khalil G M et al Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis Clin Biochem 2006 39 6 623-629 9 Huynh H Chow PK Ooi LL et al A possible role for insulinlike growth factor-binding protein-3 autocrine / paracrine loops in controlling hepatocellular carcinoma cell proliferation J Cell Growth Differ 2002 13 3 115-122 10 Scharf J G Braulke T The role of the IGF axis in hepatocarcinogenesis J Horm Metab Res 2003 35 11-12 IGF 685-693 IGF 11 Price J A Kovach S J of hepatocellualr carcinoma J 1089-1097 Johnson T et al Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model 13 Lund P Schubert D Niketeghad F et al Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin- IGF IGF like growth factor-Ⅱ J 14 Breuhahn K hepatocarcinogenesis J Hepatology 2002 36 5 12 Kasprzak H A Trojan J Bierwagen M et al Usefulness of the antisense and triplex anti-igf-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1 J Neurol Neurochir Pol 2006 40 6 509-515 Cancer Lett 2004 206 1 85-96 Molecular mechanisms of progression in human Pathologe 2010 31 S2 170-176 15 Nussbaum T Samarin J Ehemann V et al Autocrine insulin-

396 27 like growth factor-Ⅱ stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis J Hepatology 2008 48 1 146-156 16 Vu T H Nguyen A H Hoffman A R Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells J Hum Mol Genet 2010 19 5 901-919 17 Li X Nong Z Ekstrom C et al Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma J Cancer Res 1997 57 10 2048-2054 18 Thorgeirsson SS Grisham J W Molecular pathogenesis of human hepatocellular carcinoma J Nat Genet 2002 31 4 339-346 19 Tang S H Yang D H Huang W et al Differential promoter usage for insulin-like growth factor-Ⅱ gene in Chinese hepatocellular carcinoma with hepatitis B virus infection J Cancer Detect Prev 2006 30 2 192-203 20 Tang S H Yang D H Huang W et al Hypomethylated P4 promoter induces expression of the insulin-like growth factor-Ⅱ gene in hepatocellular carcinoma in a Chinese population J Clin Cancer Res 2006 12 14 Pt 1 4171-4177 21 Sun Q Zhang Y Liu F et al Identification of candidate biomarkers for hepatocellular carcinoma through pre-cancerous expression analysis in an HBx transgenic mouse J Cancer Biol Ther 2007 6 10 1532-1538 22 Liu Z Yue WT LI Q Research Progress on the Relationship between Insulin-like Growth Factor-I and Lung Cancer J Chin J Lung Cancer 2010 13 6 642-647 23 Morgillo F Woo J K Kim E S et al Heterodimerization of insulin-like growth factor receptor / epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib J Cancer Res 2006 66 20 10100-10111 25 Jones R A Campbell C I Gunther E J et al Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation J Oncogene 2007 26 11 1636-1644 26 Lopez T Hanahan D Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis J Cancer Cell 2002 1 4 339-353 24 Desbois-Mouthon C Cacheux W Blivet-Van Eggelpoel M J et al Impact of IGF-1R / EGFR cross-talks on hepatoma cell sensitivity to gefitinib J Int J Cancer 2006 119 11 2557-2566 27 Cadoret A Desbois-Mouthon C Wendum D et al c-mycinduced hepatocarcinogenesis in the absence of IGF-I receptor J Int J Cancer 2005 114 4 668-672 28 Tanaka S Arii S Molecularly targeted therapy for hepatocellular carcinoma J Cancer Sci 2009 100 1 1-8 29 Alexia C Fallot G Lasfer M An evaluation of the role of insulin-like growth factors IGF and of type-i IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis J Biochem Pharmacol 2004 68 6 1003-1015 30 Sedlaczek N Hasilik A Neuhaus P et al Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis J Br J Cancer 2003 88 5 733-739 31 Hebert E Mannose-6-phosphate / insulin-like growth factor Ⅱ receptor expression and tumor development J Biosci Rep 2006 26 1 7-17 32 Samani A A Yakar S LeRoith D et al The role of the IGF system in cancer growth and metastasis overview and recent insights J Endocr Rev 2007 28 1 20-47 33 Yamada P M Lee K W Perspectives in mammalian IGFBP-3 biology local vs systemic action J Am J Physiol Cell Physiol 2009 296 5 C954-C976 34 Ricort J M Binoux M Insulin-like growth factor binding protein- 3 stimulates phosphatidyl inositol 3-kinase in MCF-7 breast carcinoma cells J Biochem Biophys Res Commun 2004 314 4 1044-1049 35 Ricort J M Lombet A Lassarre C et al Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells J FEBS Lett 2002 527 1-3 293-297 36 Ricort J M Binoux M Insulin-like growth factor-binding protein- 3 activates a phosphotyrosine phosphatase Effects on the insulinlike growth factor signaling pathway J J Biol Chem 2002 277 22 19448-19454 37 Yin Y Ni J Chen M et al The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3 J Clin Cancer Res 2007 13 7 2271-2280 38 Serrano D Baglietto L Johansson H et al Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer J Clin Cancer Res 2005 11 5 2083-2088 39 Flanagan J N Young M V Persons K S et al Vitamin D metabolism in human prostate cells implications for prostate cancer chemoprevention by vitamin D J Anticancer Res 2006 26 4A 2567-2572 40 Peng L Wang J Malloy P J et al The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells J Int J Cancer 2008 122 3 558-566 41 López-Calderero I Sánchez Chávez E García-Carbonero R The insulin-like growth factor pathway as a target for cancer therapy J Clin Transl Oncol 2010 12 5 326-338